Novartis’s Kisqali Strikes Gold In Adjuvant Early Breast Cancer Setting
$3bn More In Sales Projected
Executive Summary
The Swiss major’s CDK4/6 inhibitor has met the primary endpoint in a pivotal breast cancer trial earlier than expected, with success in the intermediate risk group representing a $4bn opportunity untapped by rival Eli Lilly.
You may also be interested in...
Another US Generic To $3bn Ibrance Passes Muster – When Will They Launch?
A sizeable small-molecule opportunity, Pfizer’s Ibrance, is in the crosshairs for several major ANDA sponsors in the US, with Zydus the latest company to receive a tentative nod from the FDA.
ASCO Preview: Five Top Late-Breakers To Watch For
AstraZeneca plans to unveil multiple major data packages, while Servier reveals much-anticipated results in glioma, and ImmunoGen and Novartis will present key pivotal data in women’s cancers.
Novartis Culls Pipeline As ‘Pure-Play’ Drive Progresses
The Swiss company has raised its 2023 forecast thanks to stronger Q1 sales, but its transformation towards a more ‘pure-play’ pharma company is still a work in progress.